Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Conditions
Brief summary
This phase I/II trial tests the safety, side effects, best dose and effectiveness of golcadomide in combination with rituximab in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Golcadomide may help block the formation, growth or spread of cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Giving golcadomide in combination with rituximab may better treat patients with relapsed or refractory mantle cell lymphoma.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the safety and tolerance of golcadomide in mantle cell lymphoma (MCL) patients who were resistant or intolerant to covalent bruton's tyrosine kinase inhibitors (cBTKi). II. To evaluate the safety and tolerance of golcadomide in combination with rituximab in MCL patients who were resistant or intolerant to cBTKi. III. To estimate the efficacy of golcadomide and rituximab in MCL patients who were resistant or intolerant to cBTKi. SECONDARY OBJECTIVES: I. To evaluate the complete response rate (CR) of the combination of golcadomide and rituximab. II. To evaluate the durability of response by the duration of response (DOR) and duration of complete response (DOCR). EXPLORATORY OBJECTIVES: I. Correlate clinical response with changes in baseline T cell characteristics and cytokine profiles. II. To measure the rate of minimal residual disease undetectability in responding patients. OUTLINE: This is a phase I, dose-escalation study of golcadomide followed by a phase II study. Patients are assigned to 1 of 2 phases. PHASE I: Patients receive golcadomide orally (PO) once daily (QD) on days 1-14 of each cycle. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and positron emission tomography (PET)/computed tomography (CT) throughout the trial. Patients undergo bone marrow biopsy and may undergo tissue biopsy on study. PHASE II: Patients receive golcadomide PO QD on days 1-14 of each cycle. Patients also receive rituximab intravenously (IV) on days 1, 8, 15 and 22 of cycle 1 and then day 1 of even cycles. Cycles repeat every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and PET/CT throughout the trial. Patients undergo bone marrow biopsy and may undergo tissue biopsy on study. After completion of study treatment, patients are followed up at 30 days, and then up to 3 years.
Interventions
PROCEDUREBiopsy Procedure
Undergo tissue biopsy
PROCEDUREBiospecimen Collection
Undergo blood sample collection
PROCEDUREBone Marrow Biopsy
Undergo bone marrow biopsy
PROCEDUREComputed Tomography
Undergo PET/CT
DRUGGolcadomide
Given PO
PROCEDUREPositron Emission Tomography
Undergo PET/CT
BIOLOGICALRituximab
Given IV
Sponsors
City of Hope Medical Center
National Cancer Institute (NCI)
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Documented informed consent of the participant and/or legally authorized representative * Agreement to allow the use of archival tissue from diagnostic tumor biopsies * If unavailable, exceptions may be granted with study principal investigator (PI) approval * Ability to adhere to the study protocol * Age: ≥ 18 years * Eastern Clinical Oncology Group (ECOG) ≤ 2 * Histologically confirmed diagnosis of MCL * Immunohistochemistry of the biopsy * Flow cytometry of the biopsy * Relapsed/ refractory disease * Relapsed/refractory (R/R) MCL after at least one line of therapy including resistant or intolerant to a cBTKi * Fully recovered from the acute toxic effects (except alopecia) to ≤ grade 1 to prior anti-cancer therapy * Ability to swallow pills * Without bone marrow involvement: Absolute neutrophil count (ANC) \> 1.5 × 10\^9/L (ANC \> 1,500/mm\^3) * With bone marrow involvement: ANC \> 1.0 × 10\^9/L (ANC \> 1000/mm\^3) * NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement. For patients with significant marrow involvement, eligibility may be confirmed at the discretion of the treating investigator * Without bone marrow involvement: Platelets ≥ 75,000/mm\^3 * With bone marrow involvement: Platelets ≥ 50,000/mm\^3 * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (≤ 1.5 × ULN if Gilbert's disease) * Aspartate aminotransferase (AST) =\< 2.5 × ULN * Alanine aminotransferase (ALT) ≤ 2.5 × ULN unless elevation is attributable to underlying disease, in which case ALT ≤ 3.0 × ULN * Creatinine clearance of ≥ 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula * If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) ≤ 1.5 × ULN. If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants * If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN. If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants * Seronegative for HIV * Seronegative for hepatitis C virus (HCV), hepatitis B virus (HBV) (surface antigen negative) * Meets other institutional and federal requirements for infectious disease titer requirements * Note Infectious disease testing to be performed within 28 days prior to day 1 of protocol therapy * Woman of childbearing potential must have a negative pregnancy test using a highly sensitive assay (minimum sensitivity 25 IU/L) performed within 10 to 14 days and again within 24 hours prior to receiving the first dose of golcadomide/BMS-986369 * Agreement by females of childbearing potential to use two effective methods of contraception simultaneously without interruption, for at least 28 days before starting study treatment, throughout the entire duration of study treatment, during dose interruptions, and for at least 28 days after the last dose of golcadomide/BMS-986369. The two methods of contraception must include one highly effective method and one additional effective method. Compliance will be documented using the Clinical Trial Pregnancy Risk Awareness Checklist, which must be completed and provided to participants at screening and prior to dispensing of study drug. An individual of childbearing potential (IOCBP) is defined as: * A person who has achieved menarche, has not undergone a documented hysterectomy or bilateral oophorectomy, and has not been naturally postmenopausal for at least 12 consecutive months. Amenorrhea resulting from medical interventions (such as cancer therapy), rather than natural menopause, does not exclude childbearing potential. Criteria: * Achievement of menarche (onset of menstruation). * No history of surgical sterilization: * No documented hysterectomy * No documented bilateral oophorectomy * Not naturally postmenopausal: * Defined as absence of menses for ≥ 12 consecutive months due to natural causes (not due to medical interventions such as chemotherapy, hormonal therapy, or radiotherapy) * Amenorrhea due to medical causes (e.g., cancer therapy, hormonal treatment) does not qualify as natural menopause and does not exclude childbearing potential
Exclusion criteria
* Chemotherapy, radiation therapy (except for palliative radiation therapy \[XRT\]), biological therapy, immunotherapy within 21 days or five half-lives (whichever is shorter for non-radiation therapy) prior to day 1 of protocol therapy * Strong CYP3A4 inducers/ inhibitors within 14 days prior to day 1 of protocol therapy * Herbal medications * History of metastatic cancer * Unstable cardiac disease as defined by one of the following: * Cardiac events such as myocardial infarction (MI) within the past 6 months * New York Heart Association (NYHA) heart failure class III-IV * Uncontrolled atrial fibrillation or hypertension * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents * Clinically significant uncontrolled illness * Known seropositive or active infection with HIV, HBV, or HCV * Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection (as evaluated by the investigator) within 4 weeks prior to the first study treatment * Females only: Pregnant or breastfeeding * Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of dose limiting toxicities (DLT) | During cycle 1 (Cycle length = 28 days) | The adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v 5.0). Toxicity will be summarized by type, severity, and attribution. DLT will be individually described. |
| Maximum tolerated dose (MTD) of golcadomide | Up to 3 years | If single agent is tolerable, we will subsequently explore golcadomide in combination with rituximab. |
| MTD of golcadomide in combination with rituximab | Up to 3 years | Patients would remain on therapy until unacceptable toxicity, treating physician discretion or PD. |
| Overall response rate (ORR) | Up to 3 years | Defined as achieving a best response of either complete metabolic response (CMR) or partial metabolic response (PMR) in a response-evaluable participant after the start of protocol therapy and prior to disease progression and/or start of other anti-lymphoma therapy. ORR will be estimated by binary proportions, along with the 95% exact binomial confidence intervals. |
| Progression free survival (PFS) | From start of protocol treatment to time of disease relapse/progression or death due to any cause, whichever occurs earlier, assessed up to 3 years | PFS will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | Up to 3 years | Will be graded by NCI CTCAE v 5.0. Toxicity will be summarized by type, severity, and attribution. |
| Duration of response (DOR) of the combination of golcadomide and rituximab | From the first achievement of PMR or CMR to time of progressive disease (PD) or death, whichever earlier, assessed up to 3 years | DOR will be estimated using the product-limit method of Kaplan and Meier. |
| Duration of complete response (DOCR) of the combination of golcadomide and rituximab | Time from the first achievement of CMR to time of PD or death, whichever earlier, assessed up to 3 years | DOCR will be estimated using the product-limit method of Kaplan and Meier. |
| Complete response (CR) of the combination of golcadomide and rituximab | Up to 3 years | CR rate will be estimated by binary proportions, along with the 95% exact binomial confidence intervals. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORTycel J Phillips
City of Hope Medical Center
Outcome results
None listed